ライフサイエンスコーパス: fatal outcome

1 eightfold during therapy, and the case had a fatal outcome.

2 day 1 a 12-fold increased relative risk of a fatal outcome.

3 d and on day 6 a nine-fold increased risk of fatal outcome.

4 ogressive neurologic disease and an eventual fatal outcome.

5 e brain is the target organ and produces the fatal outcome.

6 was no association between TNF genotype and fatal outcome.

7 Metastatic cancer in adults usually has a fatal outcome.

8 mpanied by progressive pulmonary opacity and fatal outcome.

9 ve clinical syndrome of unknown etiology and fatal outcome.

10 underlying liver disease was associated with fatal outcome.

11 n (P < .01) was positively associated with a fatal outcome.

12 the time of infection were protected from a fatal outcome.

13 r factors that may alter the likelihood of a fatal outcome.

14 (IPF) is a progressive clinical syndrome of fatal outcome.

15 was reversible in all but one patient with a fatal outcome.

16 l cord and cervical vessels and often have a fatal outcome.

17 1 year after transplantation with a rapidly fatal outcome.

18 ) and respiratory failure with a potentially fatal outcome.

19 transmission of varicella-zoster virus with fatal outcome.

20 ed intracranial pressure may contribute to a fatal outcome.

21 ons in TREX1 experience an earlier onset and fatal outcome.

22 high-risk NB relapses after treatment with a fatal outcome.

23 ication in thrombocytopenia with a potential fatal outcome.

24 had a prenatal or perinatal onset with early fatal outcome.

25 ate that EBOV viremia may be associated with fatal outcome.

26 cases to determine clinical risk factors for fatal outcome.

27 children had bacteremia, and 16 (59%) had a fatal outcome.

28 nformation on the management of cases with a fatal outcome.

29 onatal multisystem disease and have an early fatal outcome.

30 P = .022) were significantly associated with fatal outcome.

31 e clinically severe presentation and rapidly fatal outcome.

32 ated blood creatine kinase levels, and early fatal outcome.

33 s with prominent pulmonary involvement and a fatal outcome.

34 tion demonstrated JCV, and she had a rapidly fatal outcome.

35 entlessly progressive conditions that have a fatal outcome.

36 in hospitalization of two patients, with one fatal outcome.

37 sis are the best independent predictors of a fatal outcome.

38 ly occluded the coronary orifice, leading to fatal outcome.

39 d treat suspected malaria all contributed to fatal outcomes.

40 treatment were significantly associated with fatal outcomes.

41 a-glutamyl carboxylase (GGCX) that often has fatal outcomes.

42 has been seen historically in patients with fatal outcomes.

43 nts, of which six (16%) were associated with fatal outcomes.

44 o quantify health levels associated with non-fatal outcomes.

45 ause severe infections in humans, often with fatal outcomes.

46 disorders, hemorrhagic lesions, and frequent fatal outcomes.

47 t account for potential herd immunity or non-fatal outcomes.

48 ed by risk-taking behaviors that can lead to fatal outcomes.

49 In swine with fatal outcomes (90 minutes of ischemia), all enzyme leve

50 an emergency setting were at high risk of a fatal outcome after NMBA-induced anaphylaxis.

51 l pneumonia and cardiac injury contribute to fatal outcomes after infection with influenza B virus an

52 entially important mechanism, accounting for fatal outcomes after successful resuscitation in 70% of

53 For PRx, those patients with a fatal outcome also had a higher (more impaired) PRx thro

54 tigation to identify factors associated with fatal outcomes among persons with poliomyelitis in Point

55 difference in mean ICP between those with a fatal outcome and functional survivors was only signific

56 icant association (P<.001) was found between fatal outcome and genotype at IL1B (nucleotide position

57 e about the characteristics of patients with fatal outcomes and the use of antiviral drug for SFTS.

58 y was designed to identify the predictors of fatal outcomes and to evaluate the effectiveness of anti

59 ransplantation per se is a risk factor for a fatal outcome, and the indication for reOLT does not app

60 ons to NMBAs, to identify risk factors for a fatal outcome, and to describe management of the cases t

61 To identify risk factors for fatal outcomes, clinical and epidemiologic data on all h

62 nt in preventing progressive disease and the fatal outcome common in IPF.

63 tially among persons with diabetes, although fatal outcomes declined less among those with type 2 dia

64 udies (yielding 17 722 incident fatal or non-fatal outcomes during 474 976 person-years at risk), we

65 evelopment of high intracranial pressure and fatal outcome following acute brain injury.

66 strictive anorexia nervosa subtype predicted fatal outcome for anorexia nervosa in males.

67 Reston virus (RESTV) to severe disease with fatal outcomes for EBOV.

68 ) or whether the calculated probability of a fatal outcome from VOD could discriminate responders fro

69 3, outlet strut fractures (OSFs), often with fatal outcomes, had been reported in 633 BSCC valves (0.

70 oncentrations were higher in patients with a fatal outcome if all in-hospital deaths were considered

71 , independent risk factors associated with a fatal outcome in a multivariate analysis were male gende

72 primary septicemia and was associated with a fatal outcome in both wound infections (relative risk [R

73 most cases pursues an inexorable course with fatal outcome in early childhood.

74 er with multiorgan involvement and a usually fatal outcome in early childhood.

75 accompanies and potentially contributes to a fatal outcome in EHF patients.

76 This cancer leads to a fatal outcome in less than 18 months.

77 solid-organ transplantation, with a related fatal outcome in less than five cases.

78 s of QA and PA in CSF were associated with a fatal outcome in Malawian children with cerebral malaria

79 result in a severe hemorrhagic fever with a fatal outcome in over 50% of human cases.

80 neumonia and subsequent renal failure with a fatal outcome in Saudi Arabia.

81 mozygosity was significantly associated with fatal outcome in the Arizona cohort (OR = 13.2 [95% CI,

82 determine mortality ratios and predictors of fatal outcome in women diagnosed as having anorexia or b

83 pectancy (HALE) summarises mortality and non-fatal outcomes in a single measure of average population

84 conorii(pRam18dRGA[AmTrCh]) elicits the same fatal outcomes in animals as its untransformed counterpa

85 sociated with severe respiratory disease and fatal outcomes in humans.

86 sociated with severe respiratory disease and fatal outcomes in humans.

87 d impaired NO bioactivity is associated with fatal outcomes in malaria.

88 ds the empirical basis for assessment of non-fatal outcomes in the GBD study.

89 nfection caused by Trichosporon inkin with a fatal outcome, in an immunocompetent patient following a

90 at presentation that were associated with a fatal outcome included fever, weakness, dizziness, diarr

91 associated with increased risks of rare but fatal outcomes, including stillbirth and neonatal mortal

92 n of ICP and PRx and their relationship with fatal outcome, indicating a potential early prognostic a

93 This animal model reveals that a fatal outcome is dominated by the host septic response,

94 s exposed to such drugs, and the potentially fatal outcome make drug-induced long QT syndrome an impo

95 Considering the <2 % rate of anaphylaxis, fatal outcomes, modest predictive value of ST, resource

96 score > or =18 was uniformly associated with fatal outcome (n = 8).

97 re horrific diseases with almost universally fatal outcomes; new therapeutics are desperately needed

98 n, the organ most frequently involved with a fatal outcome of cryptococcosis.

99 ic transmission of H7N9 and to the severe to fatal outcome of H7N9 infections in humans.

100 subcutaneous spread of S. pyogenes and to a fatal outcome of infection.

101 e the underlying mechanisms resulting in the fatal outcome of L. major infection in this gene-deficie

102 tobacco carcinogens but have a lower rate of fatal outcome of lung cancer compared with men.

103 The hazard ratio of fatal outcome of lung cancer comparing women with men wa

104 actors, notably underlying comorbidities, on fatal outcome of Middle East respiratory syndrome (MERS)

105 ng us with an immunopathogenic basis for the fatal outcome of SARS-CoV infection in the AC70 mice.

106 l withdrawal syndrome (AWS) is a potentially fatal outcome of severe alcohol dependence that presents

107 d bacterial co-infections contributed to the fatal outcome of this infection.

108 One patient had a fatal outcome of unknown cause, and one patient underwen

109 The fatal outcome of victims after initially successful resu

110 ains of mice, but C3H and FVB/N mice exhibit fatal outcomes of infection.

111 months postinjury, 133 (19%) patients had a fatal outcome; of those, 88 (78%) died from nonsurvivabl

112 ic discrimination beyond baseline values for fatal outcomes only.

113 Only early management may avoid a fatal outcome or the need for an emergency liver transpl

114 1 were significantly higher in patients with fatal outcome (p <.05, p<.01, respectively), with a sens

115 ne assessment seemed to protect women from a fatal outcome (P<.001).

116 ures) and the mortality index (the number of fatal outcomes per 10,000 exposures).

117 ephrectomy; thus, a practice with documented fatal outcomes persists.

118 All 31 patients with a fatal outcome received epinephrine in a titrated manner

119 However, the ability of ICP to predict a fatal outcome remained relatively stable over time.

120 What distinguishes fatal from non-fatal outcomes remains largely unknown, yet is key to op

121 d from gammadelta T cells and usually with a fatal outcome, remains largely unknown.

122 o acute respiratory distress syndrome with a fatal outcome reminiscent of human disease.

123 actors associated with doxycycline delay and fatal outcome, such as early gastrointestinal symptoms a

124 increased the risk of doxycycline delay and fatal outcome, such as early symptoms of nausea and diar

125 s was found to be a more direct predictor of fatal outcome than clinically observed parasitemia.

126 th type 2 diabetes had smaller reductions in fatal outcomes than controls.

127 city was sufficient to protect mice from the fatal outcome that characterizes HLH-like disease and wa

128 thdrawal may avoid the serious and sometimes fatal outcome that has been observed in this and other s

129 Considering fatal and non-fatal outcomes together, dengue was responsible for 1.14

130 , a correlation between high viral loads and fatal outcome was observed, emphasizing the importance o

131 addition to a strong association with PCP, a fatal outcome was significantly and independently associ

132 Also in patients with EVD, fatal outcome was significantly associated with higher c

133 Predictors of a fatal outcome were severe infections, particularly in sp

134 Reductions in fatal outcomes were similar in patients with type 1 diab

135 Alleles B*67 and B*15 were associated with fatal outcomes, whereas B*07 and B*14 were associated wi

136 Four patients with AFLP (12.5%) had a fatal outcome, with a corresponding perinatal mortality

137 sulted in a significantly increased risk for fatal outcome, with a relative increase in mortality of

138 blood of a second endocarditis patient with fatal outcome, with eight control strains from unrelated

139 er Injury Network prospective study having a fatal outcome within 2 years of onset.

140 Patients with fatal outcome within 3 days after onset of SAB were excl